WuXi AppTec Overview
Company Headquarters: US
Founded: 1982
Workforce: 10,001+
Company Working: WuXi AppTec’s laboratory testing division is a comprehensive and integrated testing platform for drug and medical device development. Fully integrated within WuXi AppTec, the laboratory testing division provides in-vivo and in-vitro assays from early screening through clinical sample analysis and medical device testing from development through product lifecycle management. It operates with full transparency, providing the high-quality data needed to advance the project while meeting international standards for regulatory compliance and maintaining industry-leading turnaround times.
The laboratory testing division consists of three integrated testing platforms, namely, WuXi AppTec IND (WIND) for preclinical drug development, clinical drug development, and medical device testing. Each platform is supported by the complementary capabilities of four service units, which include analytical, bioanalytical, toxicology, and DMPK services. Testing services are offered as a comprehensive package in support of global IND/NDA filings, or on a standalone basis, with customized study designs available to meet the varying needs of the diverse client base.
Strategy
Wuxi AppTec Co., Ltd. is focused on offering integrated business models to achieve remarkable results. It executed a long-tail strategy to increase the support of large global pharmaceutical companies. Moreover, the company strives to expand its service offering by implementing the “follow the project to follow the molecule” plan. It aims to bolster its customers’ operations with expertise and gradually establish a trusted partnership by providing required services during the early stages of new drug R&D. Additionally, Wuxi Apptec Co., Ltd. provides services during CRO and CDMO stage creating business opportunities in the late development and commercialization stage.
